How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-uti-with-pseudomonas-aeruginosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Complicated UTI with Pseudomonas Aeruginosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated UTI with Pseudomonas Aeruginosa (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated UTI with Pseudomonas Aeruginosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Cystadane	Cystadane	Mayo Clinic
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Complicated UTI with Pseudomonas Aeruginosa
Merck & Co. · 2 drugs in Complicated UTI with Pseudomonas Aeruginosa
Pai Holdings Pharm · 2 drugs in Complicated UTI with Pseudomonas Aeruginosa
Bristol-Myers Squibb · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Mayo Clinic · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Novartis · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Pfizer · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Poitiers University Hospital · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Recordati · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Tel-Aviv Sourasky Medical Center · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
University Hospital, Lille · 1 drug in Complicated UTI with Pseudomonas Aeruginosa
Assistance Publique - Hôpitaux de Paris · 1 drug in Complicated UTI with Pseudomonas Aeruginosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated UTI with Pseudomonas Aeruginosa:

Cite this brief

Drug Landscape (2026). Complicated UTI with Pseudomonas Aeruginosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-uti-with-pseudomonas-aeruginosa. Accessed 2026-06-10.

Complicated UTI with Pseudomonas Aeruginosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing